Stock data
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR) reported revenue of US$39.21M and net income of -US$311.35M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$39.21M | — | -US$349.40M | -US$311.35M | — |
| 2024 | US$47.07M | — | -US$261.63M | -US$223.86M | — |
| 2023 | US$78.59M | — | -US$165.53M | -US$146.96M | — |
| 2022 | US$46.83M | — | -US$161.26M | -US$154.81M | — |
| 2021 | US$72.83M | — | -US$100.53M | -US$100.22M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$65.00M | -US$61.21M | — |
| 2026-03-31 | US$34.37M | -US$69.23M | — |
| 2025-12-31 | US$2.87M | -US$86.98M | — |
| 2025-09-30 | US$2.76M | -US$82.17M | — |
| 2025-06-30 | US$11.48M | -US$76.61M | — |
| 2025-03-31 | US$22.10M | -US$65.58M | — |
| 2024-12-31 | US$7.39M | -US$70.75M | — |
| 2024-09-30 | US$3.74M | -US$62.49M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.